Meitheal Pharmaceuticals Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Kaken Obtains Aadi’s Fyarro, Comm

Coherus BioSciences has been transitioning from a focus on biosimilars to developing and commercializing its own immuno-oncology therapies – led by anti-PD-1 agent Loqtorzi (toripalimab-tpzi) – and it

Meitheal Pharmaceuticals has announced that it is adding another three biosimilars to its pipeline for the US market, with an exclusive commercial licensing agreement with its parent company Hong Kong